Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial
Background and aims The main causes of death in patients with severe Coronavirus disease-2019 (COVID-19) are acute respiratory distress syndrome (ARDS) and multiorgan failure caused by a severe inflammatory cascade. Novel treatment strategies, such as stem-cell-based therapy and their derivatives can be used to relieve inflammation in these cases. In this study, we aimed to evaluate the safety and efficacy of therapy using mesenchymal stromal cells (MSCs) and their derived extracellular vesicles in COVID-19 patients. Materials and methods COVID-19 patients with ARDS were included in this study and allocated into two study and control groups using block randomization. While all patients received recommended treatment based on guidelines from the national advisory committee for COVID-19 pandemic, the two intervention groups received two consecutive injections of MSCs (100 × $ 10^{6} $ cells) or one dose of MSCs (100 × $ 10^{6} $ cells) followed by one dose of MSC-derived extracellular vesicles (EVs). Patients were assessed for safety and efficacy by evaluating clinical symptoms, laboratory parameters, and inflammatory markers at baseline and 48 h after the second intervention. Results A total number of 43 patients (the MSC alone group = 11, MSC plus EV group = 8, and control group = 24) were included in the final analysis. Mortality was reported in three patients in the MSC alone group (RR: 0.49; 95% CI 0.14–1.11; P = 0.08); zero patient in the MSC plus EV group (RR: 0.08; 95% CI 0.005–1.26; P = 0.07) and eight patients in the control group. MSC infusion was associated with a decrease in inflammatory cytokines such as IL-6 (P = 0.015), TNF-α (P = 0.034), IFN-γ (P = 0.024), and CRP (P = 0.041). Conclusion MSCs and their extracellular vesicles can significantly reduce the serum levels of inflammatory markers in COVID-19 patients, with no serious adverse events. Trial registration IRCT, IRCT registration number: IRCT20200217046526N2. Registered 13th April 2020, http://www.irct.ir/trial/47073..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Stem cell research & therapy - 14(2023), 1 vom: 26. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zarrabi, Morteza [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Acute respiratory distress syndrome |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s13287-023-03402-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052058352 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052058352 | ||
| 003 | DE-627 | ||
| 005 | 20230627064910.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230627s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13287-023-03402-8 |2 doi | |
| 035 | |a (DE-627)SPR052058352 | ||
| 035 | |a (SPR)s13287-023-03402-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zarrabi, Morteza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background and aims The main causes of death in patients with severe Coronavirus disease-2019 (COVID-19) are acute respiratory distress syndrome (ARDS) and multiorgan failure caused by a severe inflammatory cascade. Novel treatment strategies, such as stem-cell-based therapy and their derivatives can be used to relieve inflammation in these cases. In this study, we aimed to evaluate the safety and efficacy of therapy using mesenchymal stromal cells (MSCs) and their derived extracellular vesicles in COVID-19 patients. Materials and methods COVID-19 patients with ARDS were included in this study and allocated into two study and control groups using block randomization. While all patients received recommended treatment based on guidelines from the national advisory committee for COVID-19 pandemic, the two intervention groups received two consecutive injections of MSCs (100 × $ 10^{6} $ cells) or one dose of MSCs (100 × $ 10^{6} $ cells) followed by one dose of MSC-derived extracellular vesicles (EVs). Patients were assessed for safety and efficacy by evaluating clinical symptoms, laboratory parameters, and inflammatory markers at baseline and 48 h after the second intervention. Results A total number of 43 patients (the MSC alone group = 11, MSC plus EV group = 8, and control group = 24) were included in the final analysis. Mortality was reported in three patients in the MSC alone group (RR: 0.49; 95% CI 0.14–1.11; P = 0.08); zero patient in the MSC plus EV group (RR: 0.08; 95% CI 0.005–1.26; P = 0.07) and eight patients in the control group. MSC infusion was associated with a decrease in inflammatory cytokines such as IL-6 (P = 0.015), TNF-α (P = 0.034), IFN-γ (P = 0.024), and CRP (P = 0.041). Conclusion MSCs and their extracellular vesicles can significantly reduce the serum levels of inflammatory markers in COVID-19 patients, with no serious adverse events. Trial registration IRCT, IRCT registration number: IRCT20200217046526N2. Registered 13th April 2020, http://www.irct.ir/trial/47073. | ||
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Acute respiratory distress syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cytokine release syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mesenchymal stromal cells |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cell therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Extracellular vesicles |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Shahrbaf, Mohammad Amin |4 aut | |
| 700 | 1 | |a Nouri, Masoumeh |4 aut | |
| 700 | 1 | |a Shekari, Faezeh |4 aut | |
| 700 | 1 | |a Hosseini, Seyedeh-Esmat |4 aut | |
| 700 | 1 | |a Hashemian, Seyed-Mohammad Reza |4 aut | |
| 700 | 1 | |a Aliannejad, Rasoul |4 aut | |
| 700 | 1 | |a Jamaati, Hamidreza |4 aut | |
| 700 | 1 | |a Khavandgar, Naghmeh |4 aut | |
| 700 | 1 | |a Alemi, Hediyeh |4 aut | |
| 700 | 1 | |a Madani, Hoda |4 aut | |
| 700 | 1 | |a Nazari, Abdoreza |4 aut | |
| 700 | 1 | |a Amini, Azadeh |4 aut | |
| 700 | 1 | |a Hassani, Seyedeh Nafiseh |4 aut | |
| 700 | 1 | |a Abbasi, Fatemeh |4 aut | |
| 700 | 1 | |a Jarooghi, Neda |4 aut | |
| 700 | 1 | |a Fallah, Nasrin |4 aut | |
| 700 | 1 | |a Taghiyar, Leila |4 aut | |
| 700 | 1 | |a Ganjibakhsh, Meysam |4 aut | |
| 700 | 1 | |a Hajizadeh-Saffar, Ensiyeh |4 aut | |
| 700 | 1 | |a Vosough, Massoud |4 aut | |
| 700 | 1 | |a Baharvand, Hossein |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stem cell research & therapy |d London : BioMed Central, 2010 |g 14(2023), 1 vom: 26. Juni |w (DE-627)SPR031208568 |w (DE-600)2548671-8 |x 1757-6512 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:26 |g month:06 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13287-023-03402-8 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2023 |e 1 |b 26 |c 06 | ||